NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Arsenic Trioxide in Treating Patients With Advanced Cancer of the Esophagus or Gastroesophageal Junction

Phase 2

Terminated

Conditions: Adenocarcinoma of the Esophagus
Stage III Esophageal Cancer
Stage IV Esophageal Cancer

Interventions: Drug: arsenic trioxide

First Posted Date: 2003-06-06

Last Posted Date: 2013-01-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 50

Registration Number: NCT00061958

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer

Phase 2

Completed

Conditions: Adult Primary Cholangiocellular Carcinoma
Adult Primary Hepatocellular Carcinoma
Advanced Adult Primary Liver Cancer
Cholangiocarcinoma of the Extrahepatic Bile Duct
Cholangiocarcinoma of the Gallbladder
Localized Unresectable Adult Primary Liver Cancer
Recurrent Adult Primary Liver Cancer
Recurrent Extrahepatic Bile Duct Cancer
Recurrent Gallbladder Cancer
Unresectable Extrahepatic Bile Duct Cancer

Interventions: Drug: erlotinib hydrochloride
Other: laboratory biomarker analysis

First Posted Date: 2003-06-06

Last Posted Date: 2013-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 78

Registration Number: NCT00033462

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Oblimersen in Treating Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia

Phase 1

Completed

Conditions: Waldenström Macroglobulinemia

Interventions: Biological: oblimersen sodium

First Posted Date: 2003-06-06

Last Posted Date: 2013-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 58

Registration Number: NCT00062244

Locations: 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States

and more 5 locations

Perifosine in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Phase 2

Terminated

Conditions: Head and Neck Cancer

Interventions: Drug: perifosine

First Posted Date: 2003-06-06

Last Posted Date: 2013-06-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 46

Registration Number: NCT00062387

Locations: 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸
CCOP - Northern Indiana CR Consortium, South Bend, Indiana, United States
🇺🇸
Decatur Memorial Hospital Cancer Care Institute, Decatur, Illinois, United States

and more 9 locations

Esophageal Motility and Airway Defenses Among Infants

Completed

Conditions: Infant, Premature, Diseases
Perinatal Asphyxia
Congenital Abnormalities

First Posted Date: 2003-06-06

Last Posted Date: 2017-10-06

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 65

Registration Number: NCT00062452

Locations: 🇺🇸
Columbus Childrens Hospital, Columbus, Ohio, United States

Natural History and Management of Pancreatic Lesions in Von Hippel-Lindau Disease

Completed

Conditions: Von Hippel-Lindau Disease

First Posted Date: 2003-06-06

Last Posted Date: 2018-11-14

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 340

Registration Number: NCT00062166

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Erlotinib and Celecoxib in Treating Patients With Stage IIIB or Stage IV Recurrent Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Stage IV Non-small Cell Lung Cancer
Recurrent Non-small Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer

Interventions: Drug: erlotinib hydrochloride
Drug: celecoxib
Other: laboratory biomarker analysis

First Posted Date: 2003-06-06

Last Posted Date: 2013-06-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 80

Registration Number: NCT00062101

Locations: 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States

Medical College of Georgia FitKid Project

Phase 2

Completed

Conditions: Healthy

First Posted Date: 2003-06-06

Last Posted Date: 2010-01-13

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 685

Registration Number: NCT00061841

Locations: 🇺🇸
Medical College of Georgia, Augusta, Georgia, United States

Medical and Surgical Treatment of Esophageal Reflux

Completed

Conditions: Gastroesophageal Reflux

First Posted Date: 2003-06-04

Last Posted Date: 2010-01-13

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 175

Registration Number: NCT00061724

Locations: 🇺🇸
Hines VA Medical Center, Maywood, Illinois, United States
🇺🇸
University of North Carolina, Chapel Hill, North Carolina, United States
🇺🇸
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States

Quality of Life in Pediatric Inflammatory Bowel Disease

Completed

Conditions: Crohn's Disease
Ulcerative Colitis

First Posted Date: 2003-06-04

Last Posted Date: 2010-01-13

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 350

Registration Number: NCT00061737

Locations: 🇺🇸
Children's Health Care of Atlanta, Atlanta, Georgia, United States
🇺🇸
Texas Children's Hospital, Houston, Texas, United States
🇺🇸
University of Chicago Children's Hospital, Chicago, Illinois, United States

and more 3 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy